BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheung KS, Mak LY, Liu SH, Cheng HM, Seto WK, Yuen MF, Lai CL. Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2020;11:e00236. [PMID: 33031195 DOI: 10.14309/ctg.0000000000000236] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Perisetti A, Goyal H, Yendala R, Thandassery RB, Giorgakis E. Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements. World J Gastroenterol 2021; 27(24): 3466-3482 [PMID: 34239263 DOI: 10.3748/wjg.v27.i24.3466] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yuan J, Peng Y, Hao FB, Wang YQ, Wang CR, Zhong GC. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis. Aging (Albany NY) 2021;13:7147-65. [PMID: 33658397 DOI: 10.18632/aging.202573] [Reference Citation Analysis]
3 Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. Hepatol Int 2021;15:1083-92. [PMID: 34402025 DOI: 10.1007/s12072-021-10234-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. J Viral Hepat 2021;28:1570-8. [PMID: 34435412 DOI: 10.1111/jvh.13601] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cheung KS, Mak LY, Lam LK, Fung J, Liu F, Seto WK, Yuen MF. Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. Hepatol Int 2021;15:881-91. [PMID: 33988834 DOI: 10.1007/s12072-021-10197-4] [Reference Citation Analysis]
6 Choi WM, Yip TC, Lim YS, Wong GL, Kim WR. Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. J Hepatol 2021:S0168-8278(21)02079-1. [PMID: 34592365 DOI: 10.1016/j.jhep.2021.09.017] [Reference Citation Analysis]
7 Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou Α, Yang HC, Zachou K, Liu CJ, Kourikou A, Gatselis N, Manolakopoulos S, Dalekos G, Kao JH, Hadziyannis S, Papatheodoridis GV. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Liver Int 2021. [PMID: 34890120 DOI: 10.1111/liv.15128] [Reference Citation Analysis]
8 Hui RW, Mak LY, Seto WK, Yuen MF. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: A spotlight on drugs at phase II clinical trials. Expert Opin Emerg Drugs 2022. [PMID: 35511483 DOI: 10.1080/14728214.2022.2074977] [Reference Citation Analysis]